$9.5 M

CYCC Mkt cap, 10-Jun-2019
Cyclacel Pharmaceuticals Net income (Q2, 2019)-1.8 M
Cyclacel Pharmaceuticals EBIT (Q2, 2019)-2.3 M
Cyclacel Pharmaceuticals Cash, 30-Jun-201915.2 M

Cyclacel Pharmaceuticals Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

1.1m1.7m1.9m843.0k

Revenue growth, %

60%12%(57%)

R&D expense

11.3m12.4m9.5m4.2m4.3m

General and administrative expense

7.8m5.7m5.5m5.3m5.4m

Operating expense total

19.1m18.1m15.0m9.5m9.7m

EBIT

(18.0m)(22.4m)(16.2m)(14.1m)(9.5m)(9.5m)

EBIT margin, %

(1658%)(1294%)(832%)(1679%)

Interest income

13.0k6.0k9.0k37.0k118.0k331.0k

Pre tax profit

(11.9m)(16.5m)(13.8m)(8.5m)(8.6m)

Income tax expense

1.7m3.2m2.1m2.0m993.0k1.3m

Net Income

(10.2m)(19.4m)(14.3m)(11.8m)(7.5m)(7.3m)

Cyclacel Pharmaceuticals Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

31.1m24.2m20.4m16.5m23.9m17.5m

Accounts Receivable

Inventories

3.4m4.6m4.1m

Current Assets

35.2m29.0m24.6m19.6m26.0m19.8m

PP&E

45.0k29.0k36.0k

Total Assets

35.5m29.4m24.8m19.7m26.0m19.8m

Accounts Payable

2.5m2.8m1.9m2.5m1.6m2.7m

Short-term debt

Current Liabilities

7.5m7.5m5.8m5.3m4.1m4.5m

Long-term debt

Total Debt

Total Liabilities

7.5m5.9m5.4m4.2m4.6m

Additional Paid-in Capital

317.5m331.0m342.6m350.1m365.1m365.8m

Retained Earnings

(308.8m)(323.2m)(335.0m)(342.5m)(349.8m)

Total Equity

28.0m21.7m18.8m14.3m21.8m15.3m

Financial Leverage

1.3 x1.4 x1.3 x1.4 x1.2 x1.3 x

Cyclacel Pharmaceuticals Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(10.2m)(19.4m)(14.3m)(11.8m)(7.5m)(7.3m)

Depreciation and Amortization

70.0k174.0k210.0k133.0k32.0k29.0k

Accounts Receivable

Inventories

Accounts Payable

(750.0k)666.0k(1.5m)370.0k(1.5m)554.0k

Cash From Operating Activities

(18.2m)(18.7m)(14.5m)(10.1m)(7.5m)(6.7m)

Purchases of PP&E

(3.0k)(13.0k)(39.0k)

Cash From Investing Activities

5.7m75.0k62.0k9.0k(13.0k)(39.0k)

Cash From Financing Activities

27.3m12.2m10.9m6.6m14.7m429.0k

Interest Paid

12.0k6.0k10.0k38.0k118.0k331.0k

Income Taxes Paid

970.0k1.8m2.9m2.0m1.8m1.2m

Cyclacel Pharmaceuticals Ratios

USDY, 2019

Financial Leverage

1.2 x